Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Additional 46M shares open for its own employees (or management?) to purchase with cheaper price (0.0541cent), for sure ESOS will dilute the EPS, ROE and DY.
During May, Kanger mentioned they have submit registration for Sinopharm Vaccine then around August will be the approval time which meets the expedited NPRA review cycles, hopefully the private company mentioned by Khairy today will be Kanger...
Just checked Kanger site, the vaccine business is own by its subsidiary called Jingzhou Kanger Biotech Limited (靖州康尔生物科技发展有限公司), it also Hotel and second car business at China beside from the bamboo ecosystem main business. Not bad lah, at least know how to diversify the business.
